Publications

Effects of Spironolactone on Serum Markers of Fibrosis in People at High Risk of Developing Heart Failure: Rationale, Design and Baseline Characteristics of a Proof‐Of‐Concept, Randomised, Precision‐Medicine, Prevention Trial. The Heart Omics in Aging (Homage) Trial

AuthID
P-00V-8NH

Author(s)

Pellicori, P

Ferreira, JP

Mariottoni, B

Brunner‐La Rocca, H

Ahmed, FZ

Verdonschot, J

Collier, T

Cuthbert, JJ

Petutschnigg, J

Mujaj, B

Girerd, N

González, A

Clark, AL

Cosmi, F

Staessen, JA

Heymans, S

Latini, R

Rossignol, P

Zannad, F

Cleland, JG

Document Type

Article

Year published

2020

Published

in European Journal of Heart Failure, ISSN: 1388-9842

Volume: 22, Issue: 9, Pages: 1711-1723

Indexing

Crossref^®44

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1002/ejhf.1716

Source Identifiers

ISSN: 1388-9842

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Effects of Spironolactone on Serum Markers of Fibrosis in People at High Risk of Developing Heart Failure: Rationale, Design and Baseline Characteristics of a Proof‐Of‐Concept, Randomised, Precision‐Medicine, Prevention Trial. The Heart Omics in Aging (Homage) Trial

Useful Links

Get Help

Federated Authentication (Click on the image)

Effects of Spironolactone on Serum Markers of Fibrosis in People at High Risk of Developing Heart Failure: Rationale, Design and Baseline Characteristics of a Proof‐Of‐Concept, Randomised, Precision‐Medicine, Prevention Trial. The Heart Omics in Aging (Homage) Trial

Useful Links

Get Help